Skip to content
CFPS Research Archives

TB-500 (Thymosin Beta-4)

Early human Healing & Recovery In 3 protocols 3 sources

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

01Dosing reference

Amount
2.0 - 2.5 mg per injection
Frequency
2 times per week (loading phase)
Cycle
4-6 weeks on (loading phase), followed by a maintenance dose of 2-2.5 mg once a month or bi-weekly
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

Actin Upregulation

Binds to actin, a cellular building block, promoting cell migration and proliferation.

02

Angiogenesis

Stimulates the formation of new blood vessels, improving blood flow to damaged tissues.

03

Anti-inflammatory Action

Reduces inflammatory cytokines, accelerating the healing process in injured areas.

03Human evidence

Potential in treating dry eye syndrome and neurotrophic keratitis.

Phase 2 and 3 clinical trials have explored Thymosin Beta-4 eye drops for corneal healing, showing improvements in symptom relief and tissue repair.

Pressure ulcer healing.

Early clinical studies investigated topical application for pressure ulcers, demonstrating safety and potential efficacy in accelerating wound closure.

04Preclinical evidence

Enhanced muscle and tendon repair.

Animal models of muscle injury showed that TB-500 administration accelerated tissue regeneration and reduced scar tissue formation.

Cardioprotective effects.

In rodent models of myocardial infarction, Thymosin Beta-4 promoted survival of heart muscle cells and stimulated new blood vessel growth.

05What is known vs. unknown

Reasonably established
  • Promotes rapid wound healing and tissue regeneration.
  • Reduces inflammation in injured muscles, tendons, and ligaments.
  • Stimulates angiogenesis (new blood vessel formation).
  • Increases cellular mobility through actin binding.
Unknowns & limits
  • Long-term safety of systemic administration in humans remains largely unstudied.
  • Optimal dosing protocols for athletic recovery or systemic healing are based on anecdotal evidence rather than clinical trials.
  • Potential risks regarding cellular proliferation and cancer progression need further investigation.

06Safety & regulatory context

Regulatory statusTB-500 is not approved by the FDA for human use and is sold strictly for research purposes. While naturally occurring Thymosin Beta-4 has been studied in clinical trials (primarily as topical or localized treatments), systemic injection of TB-500 lacks comprehensive human safety data. Reported side effects in anecdotal use include lethargy, head rush, and localized redness at the injection site. It is banned by the World Anti-Doping Agency (WADA) in competitive sports.

07Compared with BPC-157

TB-500 (Thymosin Beta-4) vs. BPC-157
Key difference
BPC-157 is derived from gastric juices and primarily acts through angiogenesis and nitric oxide pathways, often used for gut and tendon healing. TB-500 is a systemic peptide that works primarily through actin upregulation to promote cellular migration and muscle repair.
When researchers discuss each
Researchers often discuss BPC-157 for localized injuries, gastrointestinal issues, and tendon repair, whereas TB-500 is frequently discussed for systemic muscle recovery, flexibility, and overall tissue regeneration. They are sometimes studied together for synergistic healing effects.

08Appears in protocols

🩹 Injury Recovery Protocol

750 mcg twice/week (loading), then 750 mcg/week2x/week (weeks 1-4), then 1x/week

🐺 Wolverine Protocol

1-2 mg 2x/week (loading), then 1 mg/week2x/week (weeks 1-4), then 1x/week

🌟 The GLOW Protocol

750 mcg 2x/week (loading), then 750 mcg/week2x/week (weeks 1-4), then 1x/week

09Glossary

Actin
A protein that forms the contractile filaments of muscle cells and is involved in motion and cellular structure.
Angiogenesis
The physiological process through which new blood vessels form from pre-existing vessels.
Thymosin Beta-4
A naturally occurring peptide present in almost all animal and human cells, playing a vital role in tissue repair.

10Knowledge check

Q1What is the primary mechanism by which TB-500 promotes cellular movement and tissue repair?
Q2Which of the following is a known effect of TB-500 observed in preclinical studies?
Q3Which statement best reflects a documented limitation of TB-500 use described in the dossier?
Q4According to the dossier, which comparison between TB-500 and BPC-157 is accurate?
Q5Which statement about TB-500's regulatory or safety status is supported by the dossier?

11Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery
Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

KPV

Healing & Recovery
Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day

Wolverine Blend (BPC-157 + TB-500)

Healing & Recovery
Preclinical only

The 'Wolverine Blend' is a popular research combination of two well-known healing peptides: BPC-157 and TB-500 (Thymosin Beta-4). Research suggests that BPC-157 promotes angiogenesis and gastrointestinal healing, while TB-500 upregulates actin, facilitating cell migration and tissue repair. Together, they are studied for their synergistic potential in accelerating recovery from muscle, tendon, and ligament injuries.

BPC-157: 250-500 mcg/day; TB-500: 2-5 mg/week
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.